GLYPROVAC

In GlyProVac ApS we aim to design and develop novel, efficient bacterial vaccine candidates based on our proprietary platform technology BEMAP. Using BEMAP, we have revealed that both benign as well as disease causing bacteria such as E. coli, Pseudomonas aeruginosa and Shigella. extensively modify their proteins with distinct sugar molecules, known as O-linked glycosylations. These modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response... Based on our paradigm changing discovery we believe inclusion of these modifications are crucial for the development of efficient bacterial vaccines. We are currently establishing PoC for this novel bacterial vaccine concept in Urinary Tract Infections (UTIs) caused by E. coli with the GlyProVac antigen GPV02. GPV02 holds pan E. coli vaccine potential of not only UTIs, but also diarrhoea, neonatal sepsis and the severe infections associated with Healthcare associated UTIs.....

Also known as: GlyProVac ApS, GlyProVac LLC